Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of liposomal doxorubicin in combination with trastuzumab
2013-002684-25Phase 2Active
- Sponsor
- Southern Italy Cooperative Oncology Group
- Start
- Oct 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin and trastuzumab in HER2-enriched breast cancer (HER2+), sponsored by Southern Italy Cooperative Oncology Group. Primary endpoints: Pathological complete response rate and Clinical response rate. Started Oct 2013; status: active.
02
Drugs
pegylated liposomal doxorubicintrastuzumab
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2013-002684-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002684-25.